Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases.
Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Dawwas GK, et al. Among authors: parlett le. Inflamm Bowel Dis. 2023 Dec 5;29(12):1993-1996. doi: 10.1093/ibd/izad053. Inflamm Bowel Dis. 2023. PMID: 37043675 Free PMC article. Review.
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
Kappelman MD, Adimadhyam S, Hou L, Wolfe AE, Smith S, Simon AL, Moyneur É, Reynolds JS, Toh S, Dobes A, Parlett LE, Haynes K, Selvan M, Ma Q, Nair V, Burris J, Dorand JE, Dawwas GK, Lewis JD, Long MD. Kappelman MD, et al. Among authors: parlett le. Am J Gastroenterol. 2023 Apr 1;118(4):674-684. doi: 10.14309/ajg.0000000000002068. Epub 2022 Nov 26. Am J Gastroenterol. 2023. PMID: 36508681
Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib.
Kappelman MD, Long MD, Zhang X, Lin FC, Weisbein L, Chen W, Burris J, Dorand JE, Parlett LE, Fehlmann T, Brensinger CM, Haynes K, Nair V, Kaul AF, Dobes A, Lewis JD. Kappelman MD, et al. Among authors: parlett le. Crohns Colitis 360. 2023 May 29;5(3):otad031. doi: 10.1093/crocol/otad031. eCollection 2023 Jul. Crohns Colitis 360. 2023. PMID: 37350775 Free PMC article.
Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States.
Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Lewis JD, et al. Among authors: parlett le. Gastroenterology. 2023 Nov;165(5):1197-1205.e2. doi: 10.1053/j.gastro.2023.07.003. Epub 2023 Jul 20. Gastroenterology. 2023. PMID: 37481117
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS, Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B, Beachler DC, Crowe CL, Johannes CB, Juhaeri J, Lanes S, Pan C, Rothman KJ, Saltus CW, Walsh KE. Anthony MS, et al. Among authors: parlett le. Diabetes Care. 2024 Apr 1;47(4):712-719. doi: 10.2337/dc23-1911. Diabetes Care. 2024. PMID: 38363873 Free PMC article.
25 results